Diets
mediterranean diet reverses metabolic syndrome
In plain terms: Does a Mediterranean diet help reverse metabolic syndrome (waist, glucose, lipids, blood pressure)?
Part of: 🥗 mediterranean diet
Yes for its separate parts: trials show a Mediterranean diet modestly improves waist size, blood fats, blood sugar and blood pressure, but direct evidence that it reverses the syndrome itself is thin.
🧭 Read this score with how it was built in mindWe re-read the papers behind these claims and corrected how each one is counted
Rose because rows that had been voting against it were found to be off-subject (olive oil alone is not a Mediterranean diet) or double counts, and because meta-analyses that had been filed neutral report all five components of the syndrome moving the right way. What remains is mostly component evidence; the one analysis of reversal of the syndrome itself rates its own certainty low. Nothing new confirmed the claim; fewer things now count against it.
🧭 Read this score with how it was built in mindStudies that measured a neighbour of the claim can no longer carry a strong verdict
Six of the nine counting studies measured the syndrome's separate components, visceral fat or gut bacteria rather than whether the syndrome itself reversed. The three that measured reversal directly do support it, but they are a six-month trial, a retrospective clinic series and a cross-sectional survey.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
Capped to leans-support: the raw score reads strong, but it is carried mostly by the syndrome's components rather than by reversal of the syndrome itself, and those rows are now marked indirect. A meta-analysis of 57 controlled trials found a Mediterranean diet moves all five components the right way — waist −1.47 cm, triglycerides −12.3 mg/dL, fasting glucose −2.98 mg/dL, HDL +1.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Montemayor S, Mascaró CM, Ugarriza L, Casares M, Llompart I, Abete I, Zulet MÁ, Martínez JA, Tur JA, Bouzas C 2022 · Nutrients | observational | supports | low | FLIPAN randomized lifestyle trial with a customized MedDiet reduced NAFLD and improved metabolic-syndrome features in MetS patients. |
| Reinoso-Barbero L, Muñoz-Dueñas P, Redondo-Lavirgen M, Ferrández C, Gómez-Paredes L, Muñoz-Gutiérrez J, Pérez-Herreras C, Gómez-Gallego F, Fernández-Montero A 2026 · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis | observational | supports | low | Cross-sectional, n=5891 workers: MD adherence inversely assoc. w/ MetS prevalence, OR 0.45 (95% CI 0.31-0.68); components: HDL 0.63, TG 0.57, waist 0.62, glucose 0.67; BP ns 0.85 (0.70-1.04) |
| Calzada 2026 · Clin Nutr ESPEN | RCT | supports | moderate | Randomized MedDiet intervention in a non-Mediterranean (Chilean) population showed early reversal of metabolic-syndrome parameters at 6 months. |
| Galbete C, Schwingshackl L, Schwedhelm C, Boeing H, Schulze MB 2018 · Eur J Epidemiol | observational | tested-null | low | The umbrella's inclusion criteria enumerate the endpoints exhaustively — '(4) study endpoints include overall cancer mortality and/or incidence, CVD or coronary heart disease (CHD) mortality and/or incidence, stroke, myocardial infarction (MI), acute myocardial infarction (AMI) type 2 diabetes, Alzheimer's disease (AD), mild cognitive impairment (MCI), or dementia' — metabolic syndrome is not among them, and the phrases 'metabolic syndrome', 'waist circumference', 'triglyceride', 'HDL' and 'blood pressure' appear nowhere in the full text including references. It is also an umbrella of incidence meta-analyses in prospective cohorts, which cannot speak to reversion of an already-present condition. |
| Chatzi CA, Basios A, Markozannes G, Ntzani EE, Tsilidis KK, Kazakos K, Agouridis AP, Barkas F, Pappa M, Katsiki N, Rizos EC 2024 · Nutrients | meta-analysis | supports | moderate | Umbrella review: 'we finally included 25 meta-analyses with a total of 329 associations' of dietary patterns on risk factors in adults with a cardiometabolic risk factor. Endpoints are individual risk factors, not metabolic-syndrome reversal. Units are meta-analyses — review, zero weight. |
| Ruiz-Canela M, Corella D, Martínez-González MÁ, Babio N, Martínez JA, Forga L, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Santos-Lozano JM, Serra-Majem L, Bueno-Cavanillas A, Tur JA, Martín-Sánchez V, Riera-Mestre A, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Vázquez C, Daimiel L, Buil-Cosiales P, Shyam S, Sorlí JV, Castañer O, García-Rios A, Torres-Collado L, Gómez-Gracia E, Zulet MÁ, Konieczna J, Casas R, Cano-Ibáñez N, Tojal-Sierra L, Bernal-López RM, Toledo E, García-Gavilán J, Fernández-Carrión R, Goday A, Arenas-Larriva AP, González-Palacios S, Schröder H, Ros E, Fitó M, Hu FB, Tinahones FJ, Salas-Salvadó J 2025 · Ann Intern Med | RCT | supports | high | PREDIMED-Plus, n=4746, all with metabolic syndrome AT BASELINE (entry criterion). The paper's stated outcomes are 'Diabetes incidence was based on the American Diabetes Association criteria. Anthropometric measurements were obtained annually.' - metabolic-syndrome reversion or remission is never reported. The only MetS-adjacent result is directional and unquantified in the abstract: 'The intervention group attained better adherence to the erMedDiet, higher physical activity levels, and greater reductions in body weight and waist circumference.' The prior extract's 'improved cardiometabolic risk' is not a finding the paper states. Off-scope: wrong outcome, and both arms received a Mediterranean diet. |
| Haro C, García-Carpintero S, Rangel-Zúñiga OA, Alcalá-Díaz JF, Landa BB, Clemente JC, Pérez-Martínez P, López-Miranda J, Pérez-Jiménez F, Camargo A 2017 · Mol Nutr Food Res | RCT | mixed | low | CORDIOPREV substudy showed both Mediterranean and low-fat diets partially restored gut microbiota in metabolically dysfunctional obese patients, with effect depending on baseline dysfunction. |
| Eichelmann F, Prada M, Sellem L, Jackson KG, Salas Salvadó J, Razquin Burillo C, Estruch R, Friedén M, Rosqvist F, Risérus U, Rexrode KM, Guasch-Ferré M, Sun Q, Willett WC, Martinez-Gonzalez MA, Lovegrove JA, Hu FB, Schulze MB, Wittenbecher C 2024 · Nat Med | observational | tested-null | low | The paper's endpoints are lipidome change and incident disease counts only — 'Importantly, these analyses are restricted to T2D risk.' — and its PREDIMED analysis reports T2D incidence by baseline lipidomic stratum (42%, 95% CI: 15% to 61% reduction below median rMLS; 3%, 95% CI: 36%-decrease to 48%-increase above it), never MetS status, MetS components as a syndrome definition, or remission. The term 'metabolic syndrome' does not occur in the article. |
| Papadaki A, Nolen-Doerr E, Mantzoros CS 2020 · Nutrients | meta-analysis | supports | moderate | Meta-analysis of 57 controlled trials (84 papers, n=36,983; PROSPERO CRD42019141459), MD vs control in adults. All five MetSyn components moved favourably: waist -1.47 cm (-2.54 to -0.39; 27 trials), SBP -1.34 mmHg (-2.00 to -0.67), glucose -2.98 mg/dL (-4.54 to -1.42), HDL +1.30 mg/dL (0.38-2.21), TG -12.30 mg/dL (-15.60 to -8.99); I2 93-99%, Egger small-study effects for waist, SBP, DBP, TG. MetSyn INCIDENCE (one trial, PREDIMED, n=5801) NOT reduced: HR 1.10 (0.94-1.30) olive oil, 1.08 (0.92-1.27) nuts - prevention, not reversal. No reversal/remission endpoint pooled. Indirect: component surrogates in general adult populations. |
| Klein H, Alufer L, Goldberg Toren DT, Pachter D, Kamer O, Ebstein Karamani N, Chassidim Y, Shelef I, Rudich A, Yoel U, Ben-Arie G, Zelicha H, Yaskolka Meir A, Tsaban G, Bartal C, Blüher M, Stumvoll M, Ceglarek U, Isermann B, Qi L, Stampfer MJ, Hu FB, Shai I 2026 · Circulation | RCT | supports | high | 5- and 10-year follow-up of CENTRAL and DIRECT-PLUS RCTs linked (green-)Mediterranean-diet-induced visceral fat loss to durable improvement in cardiometabolic profile. |
| Salas-Salvadó J, Guasch-Ferré M, Lee CH, Estruch R, Clish CB, Ros E 2015 · J Nutr | RCT | supports | high | Review anchored on PREDIMED RCT: MedDiet promoted reversion of metabolic syndrome (notably hyperglycemia and central obesity); RCT meta-analysis showed benefit on all MetS components. |
| Zhou L, Liu H, Ma Y 2026 · Frontiers in nutrition | observational | supports | moderate | Retrospective, n=1300 older adults w/ MetS; MedDiet-style + multi-component nutrition care; 41.4% partial/total MetS resolution; component deltas (glucose -7.9mg/dL, TG -24.9, HDL/LDL, waist -3.8cm, SBP -7.7mmHg) |
| Hernandez AV, Marti KM, Marti KE, Weisman N, Cardona M, Biello DM, Pasupuleti V, Benites-Zapata VA, Roman YM, Piscoya A 2025 · J Am Nutr Assoc | meta-analysis | supports | low | SR/MA of 26 RCTs (n=10,352) in overweight/obese adults without CVD (MetS allowed, not required). Of the MetS components only two fell significantly: waist -2.48 cm (-3.99 to -0.96; 17 RCTs) and TG -7.93 mg/dL (-13.48 to -2.39; 19 RCTs; Egger p<0.05). HDL +0.74 mg/dL (-0.35 to 1.83; 18 RCTs) and SBP -1.7 mmHg (-4.39 to 0.99; 14 RCTs) non-significant; glucose -0.2 mg/dL (-0.61 to 0.21; 17 RCTs) null. 'MED did not significantly change any other CV risk factors. QoE was very low for most of the outcomes; 85% of RCTs had some concerns or high risk of bias.' No MetS reversal endpoint. Indirect: partial component surrogates. |
| Chan BS, Yu DSF, Wong CWY, Li PWC 2025 · Eur J Prev Cardiol | meta-analysis | mixed | low | Bayesian NMA of 98 RCTs (12,813 adults with metabolic syndrome). 'Pairwise meta-analysis demonstrated that multi-modal interventions outperformed exercise interventions in reversing metabolic syndrome.' MedDiet appears only in a pooled class: 'a diet promoting moderate macronutrient intake (caloric restriction, DASH and Mediterranean diets) combined with supervised aerobic exercise training or professional physical activity advice or counselling consistently yielded superior beneficial effects on metabolic syndrome, which was supported by a low certainty of evidence.' No MedDiet-alone estimate in the abstract (cannot-tell); pooled exposure and combination - indirect. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.